DDAH1 and cardiovascular disorder: Whilst upregulation of DDAH1 has been originally investigated as a therapeutic strategy to reduce ADMA and NMMA concentrations in conditions characterized by impaired NO synthesis, e.g., atherosclerosis and cardiovascular disease [4,9,10,11], more recently studies have also focused on DDAH1 inhibition to counteract the negative effect of excessive local and/or systemic NO concentrations in other disease states, e.g., cancer and sepsis [12,13,14,15,16,17,18,19,20,21].